英文名稱 | Carfilzomib | PR-171 |
---|---|
中文名稱 | 卡非佐米 |
CAS號(hào) | 868540-17-4 |
分子式 | C40H57N5O7 |
分子量 | 719.91 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Carfilzomib | PR-171 |
---|---|
中文名稱 | 卡非佐米 |
CAS號(hào) | 868540-17-4 |
分子式 | C40H57N5O7 |
分子量 | 719.91 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
PMID: 17591945 PMCID: PMC2200918 DOI: 10.1182/blood-2007-01-065888
PMID: 23990113 DOI: 10.1158/1535-7163.MCT-13-0156
Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
PMID: 25972243 DOI: 10.1530/ERC-14-0510